Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
Yu S, Lin T, Nie D, Zhang Y, Sun Z, Zhang Q, Wang C, Xiong M, Fan Z, Huang F, Xu N, Liu H, Yu G, Zhang H, Shi P, Xu J, Xuan L, Guo Z, Wu M, Han L, Xiong Y, Sun J, Wang Y, Liu Q.
Yu S, et al.
Blood Cancer J. 2021 Dec 6;11(12):195. doi: 10.1038/s41408-021-00591-4.
Blood Cancer J. 2021.
PMID: 34873148
Free PMC article.